PubMed Health⌕ Search

Biomedical subjects

J G Richards

Publications and source records attributed to J G Richards.

At least 19 recordsLinked to original sources
PubMed1992

Comparative molecular neuroanatomy of cloned GABAA receptor subunits in the rat CNS.

gamma-Aminobutyric acidA (GABAA) receptors in the mammalian central nervous system (CNS) are members of a family of ligand-gated ion channels consisting of heterooligomeric glycoprotein complexes in synaptic and extrasynaptic membranes. Although molecular cloning studies have identified 5 subunits (with approximately 40% amino acid homology) and isoforms thereof (approximately 70% homology), namely alpha 1-6, beta 1-4, gamma 1-3, delta, and rho, the subunit composition and stoichiometry of native receptors are not known. The regional distribution and cellular expression of GABAA receptor messenger RNAs (mRNAs) in the rat CNS have now been investigated by in situ hybridization histochemistry with subunit-specific 35S-labelled oligonucleotide probes on adjacent cryostat sections. Whereas alpha 1, beta 2, and gamma 2 transcripts were the most abundant and ubiquitous in the rat brain--correlating with the radioautographic distribution of GABAA receptors revealed by an ionophore ligand--others had a more restricted expression while often being abundant. For example, alpha 2 transcripts were found only in the olfactory bulb, cerebral cortex, caudate putamen, hippocampal formation, and certain lower brain stem nuclei; alpha 3 only in the olfactory bulb and cerebral cortex; alpha 5 in the hippocampal formation; and alpha 6 only in cerebellar granule cells. In addition, beta 1, beta 3, gamma 1, and delta mRNAs were also uniquely expressed in restricted brain regions. Moreover, in the spinal cord, alpha 1-3, beta 2,3, and gamma 2 mRNAs were differently expressed in Rexed layers 2-9, with alpha 2, beta 3, and gamma 2 transcripts most prominent in motoneurons of layer 9. Although differential protein trafficking could lead to the incorporation of some subunits into somatic membranes and others into dendritic membranes, some tentative conclusions as to the probable composition of native proteins in various regions of the CNS may be drawn.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1992

Biochemistry and pharmacology of moclobemide, a prototype RIMA.

RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro. This inhibition is reversible by dialysis in vitro, which accounts for the dose-dependent duration of in vivo enzyme inhibition of 12-24 h. Moclobemide increases the content of serotonin, noradrenaline and dopamine in the brain, and decreases that of their deaminated metabolites. Its biochemical, neurological and behavioural effects indicate that it increases the extracellular concentration of the classic monoamine neurotransmitters/neuromodulators - in particular 5-HT. Potentiation of the cardiovascular effects of tyramine is less pronounced after taking moclobemide than after irreversible MAO-A inhibitors. Understanding of the physiological role of MAO and of the events that link inhibition of the enzyme with modulation of neuronal activities in the CNS remains incomplete. A major physiological role of intraneuronal MAO is to keep cytosolic amine concentration very low, to enable the neuronal monoamine carriers to produce a net inward transport of monoamines, and thereby to act as the first step in the termination of action of extracellular monoamines. MAO is likely to have a similar function in non-monoaminergic cells with respect to the monoamine carriers they contain. In addition to the classic monoamines, "trace" amines may become functionally active after MAO inhibition. An alternative role for MAO is that of a scavenger, preventing natural substrates from accumulating in monoaminergic neurons and interacting with storage, release, uptake and receptor function of monoamines.

Animals↗
PubMed1992

Molecular neuroanatomy of monoamine oxidases in human brainstem.

Specific, high-resolution techniques (quantitative enzyme radioautography and in situ hybridisation histochemistry) have revealed distribution, abundance and cellular localization of the isoenzymes MAO-A and MAO-B and their mRNAs in human post-mortem brainstem. Whereas MAO-A protein and mRNA are expressed by noradrenergic neurons of the locus coeruleus, MAO-B protein and mRNA are expressed by serotoninergic neurons of the raphé nuclei. In the substantia nigra, MAO-B was more abundant than MAO-A; the former was localized in the reticular zone and the latter in the compact zone (where melanin-containing dopaminergic neurons are found). To date, it has not been possible to detect mRNA for either MAO-A or MAO-B in the substantia nigra or in glial cells of the brain regions investigated, suggesting either that the technique has limited sensitivity, or the possible existence of MAO-A and MAO-B subtypes.

Aged↗
PubMed1992

Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.

The classic benzodiazepines produce anxiolytic, anticonvulsant, sedative and myorelaxant effects at overlapping dose ranges. Efforts to reduce the sedative/myorelaxant component of this profile has a long history. Two rational approaches might theoretically lead to the desired drugs. One is based on the combination of partial (low efficacy) agonists of the benzodiazepine receptor with different receptor reserves in neurons subversing various functions. The other approach is based on the existence of GABAA-benzodiazepine receptor polymorphism and assumes that distinct receptor variants may be more prevalent on neurons involved in various CNS functions. Results are presented that were obtained with the partial agonist bretazenil and three other ligands in vitro as well as in vivo. Curves relating fractional receptor occupancy and various effects (potentiation of GABA-induced chloride flux, anticonvulsant, anticonflict and sedative effects) are fully consistent with the view that the particular profile of activity of bretazenil is the result of partial agonism. Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order. Clinical aspects of partial benzodiazepine receptor agonists are discussed on the basis of the preliminary information available to date.

Animals↗
PubMed1992

Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain.

Monoamine oxidases A and B (MAO-A and MAO-B) oxidatively deaminate neurotransmitter and xenobiotic amines. Since the cellular localization of the isoenzymes in the CNS and peripheral organs determines to a large extent which substrate has access to which isoenzyme, knowledge of their tissue distribution and cellular localization is essential. Here we describe how reversible and selective inhibitors of MAO-A and MAO-B [Ro 41-1049 and Ro 19-6327 (lazabemide), respectively] can be used, as tritiated radioligands, to map the distribution and abundance of the enzymes in microscopic regions of the rat CNS and peripheral organs, and human brain by quantitative enzyme radioautography. The in vitro binding characteristics of both radiolabeled inhibitors revealed them to be selective, high-affinity ligands for the respective enzymes. KD and Bmax values for 3H-Ro 41-1049 in rat cerebral cortex were 10.7 nM and 7.38 pmol/mg protein, respectively, and for 3H-Ro 19-6327 were 18.4 nM and 3.45 pmol/mg protein, respectively. In accordance with their potencies as enzyme inhibitors, binding to MAO-A and MAO-B was competitively inhibited by clorgyline (IC50 = 1.4 nM) and L-deprenyl (selegiline; IC50 = 8.0 nM), respectively. The capacities of various rat and human tissues to bind the radioligands correlated extremely well with their corresponding enzyme activities. As revealed by the respective binding assays, the distribution and abundance of MAO-A and MAO-B in the tissues investigated differed markedly. MAO-A was most abundant in the locus coeruleus, paraventricular thalamus, bed nucleus of the stria terminalis, median habenular nucleus, ventromedial hypothalamus, raphe nuclei, solitary tract nucleus, inferior olives, interpeduncular nucleus, claustrum, and numerous peripheral tissues, including liver, vas deferens, heart, superior cervical ganglion, and exocrine and endocrine pancreas. In contrast, MAO-B was most abundant in the ependyma, circumventricular organs, olfactory nerve layer, periventricular hypothalamus, cingulum, hippocampal formation, raphe nuclei, paraventricular thalamus, mammillary nuclei, cerebellar Bergmann glia cells, liver, posterior pituitary, renal tubules, and endocrine pancreas. The cellular localization of the isoenzymes in both rat and human brain differs markedly and does not reflect the distribution of the presumed natural substrates, for example, absence of MAO-A in serotoninergic neurons. Indeed, the present evidence suggests that, whereas MAO-A is found in noradrenergic and adrenergic neurons, MAO-B occurs in astrocytes, serotoninergic neurons, as well as ventricular cells, including most circumventricular organs. The physiological roles of the enzymes are discussed in the light of these findings, some of which were unexpected.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1991

In situ hybridization histochemistry reveals a diversity of GABAA receptor subunit mRNAs in neurons of the rat spinal cord and dorsal root ganglia.

The distribution and relative abundance of gene transcripts for diverse GABAA receptor subunits (alpha 1-3,5, beta 1-3, gamma 2) in neurons of the rat cervical spinal cord and dorsal root ganglia were determined by in situ hybridization histochemistry using 35S-labeled 60mer oligonucleotide probes. The receptor proteins (mapped by benzodiazepine receptor radioautography and immunohistochemistry with [3H]flumazenil and a monoclonal antibody for the beta 2 + beta 3 subunits, respectively) were most abundant in the dorsal horn (layers II and III) and in layer X around the central canal. Although diverse receptor subunit mRNAs were detected (to varying degrees) in neurons throughout layers II-X of the spinal cord, motoneurons in layer IX were particularly strongly labeled. The gamma 2 mRNA was the most ubiquitous and abundant of the subunit variants investigated. The labeling of motoneurons in layer IX was particularly strong for alpha 2, moderate for beta 3 and gamma 2 and extremely weak for alpha 1 and alpha 3. In layers VII, VIII and X the beta 3 and gamma 2 transcripts were moderately expressed whereas the alpha 1 and beta 2 transcript levels differed markedly among the cells of these layers. Although the mRNAs of all subunit variants could be detected in layers IV-VI, only alpha 3, alpha 5, beta 3 and gamma 2 hybridization signals were observed in layers II and III. In the dorsal root ganglia, whereas alpha 2 transcripts were abundant in virtually all large sensory neurons and to a much lower degree in the small diameter cells, gamma 2 transcripts were confined to a subpopulation of large and small neurons. Furthermore, beta 2 and alpha 1 transcripts were even more restricted in their distribution. The findings provided a basis for the mediation of synaptic inhibition in the spinal cord by diverse GABAA receptors and further strong evidence for the long-established view that presynaptic inhibition of inter- and motoneurons, via axoaxonic synapses between GABAergic interneurons and primary afferent terminals, is mediated by GABAA receptors. The physiological roles and pharmacological implications of this receptor diversity have yet to be determined.

Animals↗
PubMed1990

Subcellular localization of GABAA/benzodiazepine receptor-like immunoreactivity in the superficial gray layer of the rat superior colliculus.

The monoclonal antibody bd-17, which recognizes the beta 2 and beta 3-subunits of GABAA/benzodiazepine receptors, was used to determine the cellular and subcellular localization of receptor-like immunoreactivity in the superficial gray layer of the rat superior colliculus. In numerous dendrites, very strong immunostaining was present in the cytoplasm and on the postsynaptic dendritic membrane of synaptic junctions. The extrasynaptic portion of the dendritic membrane also very often showed [beta 2 + beta 3]-like immunoreactivity. However, due to methodological limitations, it could not be stated with certainty whether presynaptic beta 2- and beta 3-subunits of GABAA/benzodiazepine receptors actually occur in this mesencephalic visual structure. In conclusion, these results strongly suggest that synaptic and non-synaptic GABAA/benzodiazepine receptors are present in the superficial gray layer of the rat superior colliculus. These receptors may modulate neuronal cell activity in different ways, depending on their location.

Animals↗
PubMed1990

Asthma and its management at a student health service.

Of 96 asthmatic students 62 said their asthma had not required them to give up any activity but only seven said it had not interfered in some way with their sport. Thirty-nine regarded their asthma as an annoyance and 13 of these were angered by it. Fifty-seven respondents took treatment continuously and the most favoured agent in attacks was salbutamol. Peak flow meters were not used regularly except by six students. About two-thirds had significant deficiencies in their knowledge of asthma and the most popular source of information was the general practitioner. Only 30 had read the Asthma Foundation pamphlets.

Activities of Daily Living↗
PubMed1990

Functional expression and sites of gene transcription of a novel alpha subunit of the GABAA receptor in rat brain.

Two alpha subunits of the GABAA receptor in rat brain have been identified by molecular cloning. The deduced polypeptide sequences share major characteristics with other chemically gated ion channel proteins. One polypeptide represents the rat homologue of the alpha 3 subunit previously cloned from bovine brain, while the other polypeptide is a yet known subunit, termed alpha 5. When coexpressed with the beta 1 subunit in Xenopus oocytes the receptors containing the alpha 5 subunit revealed a higher sensitivity to GABA than receptors expressed from alpha 1 + beta 1 subunits or alpha 3 + beta 1 subunits (Ka = 1 microM, 13 microM and 14 microM, respectively). The alpha 5 subunit was expressed only in a few brain areas such as cerebral cortex, hippocampal formation and olfactory bulb granular layer as shown by in situ hybridization histochemistry. Since the mRNA of the alpha 5 subunit was colocalized with the alpha 1 and alpha 3 subunits only in cerebral cortex and in the hippocampal formation the alpha 5 subunit may be part of distinct GABAA receptors in neuronal populations within the olfactory bulb.

Animals↗
PubMed1990

From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.

This study describes the serendipitous discovery of moclobemide, a short-acting MAO-A inhibitor which is in an advanced stage of clinical development as an antidepressant. The short duration of action of this MAO inhibitor containing a morpholine ring moiety is due to the complete reversibility (probably by metabolism of the inhibitory molecular species) of MAO-A inhibition. Since moclobemide is much more effective in vivo than expected from its in vitro activity, investigations to identify a possible metabolite(s) more active as MAO-A inhibitor than the parent compound were carried out. The study of the MAO inhibitory characteristics of several known and putative moclobemide metabolites did not allow the identification of a potent MAO-A inhibitor but led to the discovery of Ro 16-6491, a potent MAO-B inhibitor of novel chemical structure. Systematic chemical modification of the aromatic ring system of Ro 16-6491 finally provided Ro 19-6327 and Ro 41-1049 which are highly selective and reversible inhibitors of MAO-B and MAO-A, respectively. Tritiated derivatives of Ro 19-6327 and Ro 41-1049 were used in binding studies to elucidate their mechanisms of action and to study their cellular distribution by quantitative enzyme radioautography.

Animals↗
PubMed1990

Molecular neuroanatomy of MAO-A and MAO-B.

A selective, quantitative and high resolution technique (in vitro and in vivo enzyme radioautography) has been used to reveal the tissue distribution and abundance of MAO-A and MAO-B in the central nervous system and peripheral organs in the rat. The in vitro approach was also used to map the enzymes in human post-mortem brain. Furthermore, using in situ hybridization histochemistry, locus coeruleus and raphé neurons in the human brain were found to code for MAO-A and MAO-B respectively and not vice versa.

Animals↗
PubMed1990

GABAA-receptors: structural requirements and sites of gene expression in mammalian brain.

GABAA-receptors, the major synaptic targets for the neurotransmitter GABA, are gated chloride channels. By their allosteric drug-induced modulation they serve as molecular control elements through which the levels of anxiety, vigilance, muscle tension and epileptiform activity can be regulated. Despite their functional prominence, the structural requirements of fully functional GABAA-receptors are still elusive. Expression of cDNAs coding for the alpha 1- beta 1-subunits of rat brain yielded GABA-gated chloride channels which were modulated by barbiturates but displayed only agonistic responses to ligands of the benzodiazepine receptor. GABAA-receptors with fully functional benzodiazepine receptor sites were formed when the alpha 1- and beta 1-subunits were co-expressed with the gamma 2-subunit of rat brain. These receptors, however, failed to show cooperativity of GABA in gating the channel. In order to determine the subunit repertoire available for receptor assembly in different neuronal populations in vivo, the sites of subunit gene expression were (alpha 1, alpha 2, alpha 3, alpha 5, alpha 6, beta 1, beta 2, beta 3, gamma 2) mapped by in situ hybridization histochemistry in brain sections. The mRNAs of the alpha 1-, beta 1- and gamma 2-subunits were co-localized e.g. in mitral cells of olfactory bulb, pyramidal cells of hippocampus as well as granule cells of dentate gyrus and cerebellum. The lack of colocalization in various other brain areas points to an extensive receptor heterogeneity. The presence of multiple GABAA-receptors in brain may contribute to synaptic plasticity, differential responsiveness of neurons to GABA and to variations in drug profiles.

Animals↗
PubMed1990

GABA, GABA receptors and benzodiazepine receptors in the human spinal cord: an autoradiographic and immunohistochemical study at the light and electron microscopic levels.

The regional, cellular and subcellular distribution of GABA, GABA receptors and benzodiazepine receptors was investigated by light and electron microscopy in the human lumbar spinal cord taken post-mortem from eight cases aged 20-76 years. Firstly, the regional distribution of GABA receptors and benzodiazepine receptors was studied using autoradiography following in vitro labelling of cryostat sections with tritiated ligands. This was followed by a detailed study of the cellular and subcellular distribution and localization of GABA and benzodiazepine/GABAA receptors by light and electron microscopy using immunohistochemical techniques with monoclonal antibodies to GABA and to the alpha and beta subunits of the benzodiazepine/GABAA receptor complex. The results showed a close correspondence in the regional distributions of GABA, GABA (GABAA and GABAB) receptors and benzodiazepine receptors. The highest density of GABA-like immunoreactivity, GABA receptors and benzodiazepine receptors was localized as a dense band within lamina II of the dorsal horn (especially inner lamina II) with moderately high densities in laminae I and III. The remaining laminae of the spinal gray matter showed much lower levels of labelling. A close correspondence was also seen in the distribution of GABA-like immunoreactivity and of benzodiazepine/GABAA receptor immunoreactivity at the cellular and subcellular levels. At the cellular level, the greatest number of GABA-immunoreactive cells was found in lamina II; they comprised small, round to oval cells and, on the basis of soma size, shape, orientation and dendromorphology, they corresponded to previously described islet and filamentous cells. Benzodiazepine/GABAA receptor immunoreactivity was also localized on the same cell types in lamina II. At the subcellular level in lamina II, GABA-immunoreactive axon terminals mainly established axodendritic synaptic contacts. Small numbers of GABA-immunoreactive axon terminals appear to form possible axo-axonic contacts in complex synaptic arrays. Benzodiazepine/GABAA receptors were localized within the same types of synaptic complexes in which GABA-immunoreactive axon terminals were found. In these synaptic complexes, benzodiazepine/GABAA receptor immunoreactivity was associated with presynaptic and postsynaptic membranes and on apparent non-synaptic membranes. These results show a high concentration of GABA, GABA receptors and benzodiazepine receptors in lamina II of the dorsal horn of the human spinal cord and suggest a possible role for GABA in spinal sensory functions.

Autoradiography↗
PubMed1990

Neural elements in the pineal complex of the frog, Rana esculenta, II: GABA-immunoreactive neurons and FMRFamide-immunoreactive efferent axons.

The photosensory pineal complex of anurans comprises an extracranial part, the frontal organ, and an intracranial part, the pineal organ proper. Although the pineal organ functions mainly as a luminosity detector, the frontal organ may monitor the relative proportions of short and intermediate/long wavelengths in the ambient illumination. The major pathway of information processing in the pineal and frontal organs is the photoreceptor to ganglion cell synapse. It is not known whether interneurons form part of the neural circuitry. In the present study, we demonstrate GABA-immunoreactive (GABA-IR) neurons in the pineal and frontal organs of the frog, Rana esculenta. No GABA-IR axons were observed in the pineal nerve between the frontal and pineal organs, or in the pineal tract that connects the pineal complex with the brain. The GABA-IR neurons differed in morphology from centrally projecting neurons visualized by retrograde labeling with horseradish peroxidase. Thus, we suggest that the GABA-IR neurons in the pineal and frontal organs represent local interneurons. Axons of central origin, immunoreactive with a sensitive antiserum against the tetrapeptide Phe-Met-Phe-Arg-NH2 (FMRFamide), were observed in the intracranial portion of the photosensory pineal organ. The immunoreactive axons enter the caudal pole of the pineal organ via the posterior commissure. The largest density of axons was observed in the caudal part, while fewer axons were detected in the rostral portion. The uneven distribution of the FMRFamide-immunoreactive axons may be related to the distribution of different types of intrapineal neurons. FMRFamide-immunoreactive varicose axons were observed in the extracranial frontal organ. A central innervation of the pineal organ, previously known exclusively from amniotes, is probably not per se linked with the evolutionary transition of the pineal organ from a directly photosensory organ to a neuroendocrine organ. It could rather represent a centrifugal input to a sensory system which has been retained when the directly sensory functions have changed, during phylogeny, to neuroendocrine functions.

Animals↗
PubMed1990

In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors.

The flumazenil analogue, Ro 16-0154, a benzodiazepine partial inverse agonist, has been labeled by halogen exchange to enable SPECT investigations of central benzodiazepine receptors in the human brain. The purified 123I-Ro 16-0154 was found to be stable in rat brain preparations and to be metabolized in rat liver preparations. Its pharmacologic properties were comparable to those of flumazenil. The biodistribution in rats (1 hr postinjection) resulted in a high brain-to-blood ratio of 16. Clinical studies revealed images of the benzodiazepine receptor density in the brain. Since the receptor labeling was markedly reduced by injection of flumazenil, it was considered to be specific. Storage defects due to pathologic cerebral blood flow and changed receptor density were detected; this shows the potential usefulness of the substance for diagnostic purposes, e.g., the differential diagnosis of various forms of epilepsy.

Animals↗